KROS ▲ +0.7% - Keros Therapeutics, Inc.
$KROS - Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
28-SEP-2026 08:00 AM ET
Share this post
More filings for $KROS
KROS ▼ -1.2% - Keros Therapeutics, Inc.Sep 10, 2026KROS ▲ +0.8% - Keros Therapeutics, Inc.Sep 8, 2026$KROS SEC Filing Update (29-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 29, 2026$KROS SEC Filing Update (17-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 17, 2026
View full $KROS filing history →💬 Comments
Loading comments…
Leave a comment